Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company that uses patent protected advanced mathematical techniques for personalized medicine, says its game-changing iPhone app, MelApp, has the potential to change the face of early detection against the world’s fastest growing cancer. Within just days of release, MelApp is being used by consumers in 24 countries (United States, Canada, Australia, New Zealand, United Kingdom, Italy, Spain, Ireland, Germany, Portugal, Venezuela, Brazil, Switzerland, Sweden, Belgium, Bulgaria, Croatia, Argentina, Netherlands, Romania, Poland, Luxembourg, Greece, Turkey) as reported by tracking data from July 6 to July 10, 2011. Additionally, in just these few days, MelApp has successfully achieved the status of ranking among the top 100 highest grossing apps in 20 countries in the Healthcare and Fitness category. Health Discovery Corporation is particularly pleased to see early sales from New Zealand and Australia, which have some of the highest rates of skin cancer in the world. “Most consumers understand that early detection is critical with a cancer like Melanoma; what they need is a reliable technology literally at their fingertips that offers immediate convenience at an affordable price. Now they have it with MelApp,” explains Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are particularly pleased with the rate of downloads and global reach achieved thus far especially since we purposefully released MelApp initially as a soft launch. It’s a rewarding scenario that Health Discovery Corporation finds itself in, both for the consumers who download and use this informative app and our shareholders who could benefit from the revenue being generated by global product sales of MelApp.” Herbert A Fritshe, PhD, Chief Science Officer for Health Discovery Corp and retired Professor of Laboratory Medicine at MD Anderson Cancer Center, states, "The rapid worldwide use of MelApp appears to be proof that consumers are interested in learning more about their risk of melanoma. It is our hope that with the knowledge learned from MelApp, these consumers will seek earlier medical diagnosis and treatment when their melanoma is largely curable, ultimately potentially saving their life."
Android Coming SoonIn the U.S., where the wireless smart phone market has shifted dramatically with Android owning the largest share (38%) compared to iPhone (27%) and Blackberry (21%) according to Nielsen, Health Discovery Corporation anticipates even greater adoption when it releases an Android version of MelApp. HDC hopes to launch the Android version of MelApp within the next month. About MelApp MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center. Using the iPhone camera feature, users can take a picture of their skin lesions and moles and within seconds receive a risk analysis of their uploaded picture being a melanoma. Utilizing your iPhone GPS, MelApp can refer you to a nearby physician specializing in the diagnosis and treatment of melanoma for proper medical follow up, without the need to input a zip code or any personal information. These pictures also can be stored on MelApp and reviewed for changes in the skin lesions occurring over time. MelApp by Health Discovery Corporation launches with a special limited time introductory price of $1.99 and is currently available in the iTunes App Store. More complete details about the mobile health app can be found at http://www.melapp.net and on Facebook http://www.facebook.com/MelApp and Twitter: http://twitter.com/#!/SafeHealthApps. If you are a physician who diagnoses and treats melanoma, and would like to become a subscribed member of our physician referral network, please contact us at email@example.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6790056&lang=en